D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020;21:E1258.
Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167:267–77.
Article CAS PubMed Google Scholar
Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J, et al. Initial report from the Hunter Outcome Survey. Genet Med Off J Am Coll Med Genet. 2008;10:508–16.
Parini R, Jones SA, Harmatz PR, Giugliani R, Mendelsohn NJ. The natural history of growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2016;117:438–46.
Article CAS PubMed Google Scholar
Wiśniewska K, Wolski J, Gaffke L, Cyske Z, Pierzynowska K, Węgrzyn G. Misdiagnosis in mucopolysaccharidoses. J Appl Genet. 2022;63:475–95.
Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis. 1999;22:638–48.
Article CAS PubMed Google Scholar
Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr. 2009;154:733–7.
Scarpa M. Mucopolysaccharidosis type II. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993 [cited 2024 Jul 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1274/.
Barth AL, de Magalhães TSPC, Reis ABR, de Oliveira ML, Scalco FB, Cavalcanti NC, et al. Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up. Mol Genet Metab Rep. 2017;12:62–8.
PubMed PubMed Central Google Scholar
Sreekantam S, Smith L, Stewart C, Kearney S, Lawson S, Raiman J, et al. Efficacy of early haematopoietic stem cell transplantation versus enzyme replacement therapy on neurological progression in severe Hunter syndrome: case report of siblings and literature review. Mol Genet Metab Rep. 2022;32: 100881.
CAS PubMed PubMed Central Google Scholar
Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci. 2020;21:2975.
Article CAS PubMed PubMed Central Google Scholar
Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol. 2005;32:270–2.
Manara R, Rampazzo A, Cananzi M, Salviati L, Mardari R, Drigo P, et al. Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution. J Inherit Metab Dis. 2010;33(Suppl 3):S67-72.
Jurecka A, Krumina Z, Żuber Z, Różdżyńska-Świątkowska A, Kłoska A, Czartoryska B, et al. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. Am J Med Genet A. 2012;158A:450–4.
Ago Y, Rintz E, Musini KS, Ma Z, Tomatsu S. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. Int J Mol Sci. 2024;25:1113.
Article CAS PubMed PubMed Central Google Scholar
Kowalewski B, Lamanna WC, Lawrence R, Damme M, Stroobants S, Padva M, et al. Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice. Proc Natl Acad Sci. 2012;109:10310–5.
Article CAS PubMed PubMed Central Google Scholar
Velde HM, Reurink J, Held S, Li CHZ, Yzer S, Oostrik J, et al. Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants. Hum Genet. 2022;141:1723–38.
Article CAS PubMed PubMed Central Google Scholar
Rasheeedah I, Patrick O, Abdullateef A, Mohammed A, Sherifat K, Gbadebo I. Challenges in the management of mucopolysaccharidosis type II (Hunter’s syndrome) in a developing country: a case report. Ethiop J Health Sci. 2015;25:279–82.
Article PubMed PubMed Central Google Scholar
Chan M-J, Liao H-C, Gelb MH, Chuang C-K, Liu M-Y, Chen H-J, et al. Taiwan National Newborn Screening Program by tandem mass spectrometry for mucopolysaccharidoses types I, II, and VI. J Pediatr. 2019;205:176–82.
Article CAS PubMed Google Scholar
Chien Y-H, Lee N-C, Chen P-W, Yeh H-Y, Gelb MH, Chiu P-C, et al. Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns. Orphanet J Rare Dis. 2020;15:38.
Article PubMed PubMed Central Google Scholar
Chuang C-K, Tu Y-R, Lee C-L, Lo Y-T, Chang Y-H, Liu M-Y, et al. Updated confirmatory diagnosis for mucopolysaccharidoses in Taiwanese infants and the application of gene variants. Int J Mol Sci. 2022;23:9979.
Article CAS PubMed PubMed Central Google Scholar
Lin H-Y, Chang Y-H, Lee C-L, Tu Y-R, Lo Y-T, Hung P-W, et al. Newborn screening program for mucopolysaccharidosis type II and long-term follow-up of the screen-positive subjects in Taiwan. J Pers Med. 2022;12:1023.
Article PubMed PubMed Central Google Scholar
Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004;144:S27-34.
Article CAS PubMed Google Scholar
Filocamo M, Tomanin R, Bertola F, Morrone A. Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know. Ital J Pediatr. 2018;44:129.
Article CAS PubMed PubMed Central Google Scholar
Zanetti A, D’Avanzo F, Bertoldi L, Zampieri G, Feltrin E, De Pascale F, et al. Setup and validation of a targeted next-generation sequencing approach for the diagnosis of lysosomal storage disorders. J Mol Diagn JMD. 2020;22:488–502.
Article CAS PubMed Google Scholar
Ghaffari SR, Rafati M, Shadnoush M, Pourbabaee S, Aghighi M, Mirab Samiee S, et al. Molecular characterization of a large cohort of mucopolysaccharidosis patients: Iran mucopolysaccharidosis RE-diagnosis study (IMPRESsion). Hum Mutat. 2022;43:e1-23.
Article CAS PubMed Google Scholar
Gul R, Firasat S, Schubert M, Ullah A, Peña E, Thuesen ACB, et al. Identifying the genetic causes of phenotypically diagnosed Pakistani mucopolysaccharidoses patients by whole genome sequencing. Front Genet. 2023;14:1128850.
Article CAS PubMed PubMed Central Google Scholar
Lau H, Harmatz P, Botha J, Audi J, Link B. Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: an analysis from the Hunter Outcome Survey. Mol Genet Metab Rep. 2023;37: 101005.
PubMed PubMed Central Google Scholar
Żuber Z, Kieć-Wilk B, Kałużny Ł, Wierzba J, Tylki-Szymańska A. Diagnosis and management of mucopolysaccharidosis type II (Hunter syndrome) in Poland. Biomedicines. 2023;11:1668.
Article PubMed PubMed Central Google Scholar
Young ID, Harper PS. Mild form of Hunter’s syndrome: clinical delineation based on 31 cases. Arch Dis Child. 1982;57:828–36.
Article CAS PubMed PubMed Central Google Scholar
Jones SA, Almássy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534–43.
留言 (0)